Hypertrophic Cardiomyopathy trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Hypertrophic Cardiomyopathy. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month3 studies across 1 company, in the next 180 days.
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyNCT06146660observationalNumber of participants with adverse events | — | Recruiting | 2026-11-30 | in 102 d | 2024-11-06 |
December 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the USNCT07557498observationalParticipant blood pressure (both systolic and diastolic) | — | Recruiting | 2026-12-14 | in 116 d | 2026-04-29 |
| BMY | Bristol-Myers Squibb | Real-world Patient Reported Outcomes Among Patients Treated With CamzyosNCT06551129observationalParticipant Hypertrophic Cardiomyopathy symptoms as assessed by Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ v2,0 - 7-day recall version) | — | Recruiting | 2026-12-31 | in 133 d | 2024-11-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Hypertrophic Cardiomyopathy
most recently updated first27 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | $134.9B | A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)NCT05489705observationalIncidence rate of new or worsening heart failure due to systolic dysfunction among participants with symptomatic obstructive HCM during periods of exposure to mavacamten and other oHCM treatment | — | Recruiting | Drug: Mavacamten, Non-mavacamten symptomatic oHCM therapy | Obstructive Hypertrophic Cardiomyopathy | 1,700 | 2022-08-16 | 2029-08-17 | in 1,093 d | 2026-08-19 |
| CYTK | Cytokinetics | $10.6B | A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).NCT06412666Change from baseline in Valsalva left ventricular outflow tract gradient (LVOT-G) | Phase 2/3 | Active, not recruiting | Drug: Aficamten, Placebo | Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy | 65 | 2024-05-29 | Jan 2030 | ≤ 1,260 d | 2026-08-18 |
| EWTX | Edgewise Therapeutics, Inc. | $4.8B | A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)NCT06347159Incidence of treatment-emergent adverse events | Phase 2 | Active, not recruiting | Drug: EDG-7500, EDG-7500 | Hypertrophic Cardiomyopathy | 79 | 2024-04-11 | Dec 2027 | ≤ 498 d | 2026-07-31 |
| LXRX | Lexicon Pharmaceuticals | $1.1B | A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyNCT06481891Change from Baseline to Week 26 in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ CSS) | Phase 3 | Active, not recruiting | Drug: Sotagliflozin, Placebo | Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy | 500 | 2024-09-24 | Jul 2026 | — | 2026-07-29 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in ChinaNCT07361289observationalChange from baseline in Valsalva left ventricular outflow tract (LVOT) gradient | — | Recruiting | Drug: Mavacamten | Hypertrophic Cardiomyopathy | 500 | 2026-01-15 | 2028-08-22 | in 733 d | 2026-06-18 |
| BMY | Bristol-Myers Squibb | $134.9B | A Retrospective Cohort Study of Mavacamten Patient Support Program in CanadaNCT06549608observationalParticipant demographics | — | Completed | Drug: Mavacamten | Hypertrophic Cardiomyopathy | 683 | 2024-04-20 | 2024-05-06actual | — | 2026-06-12 |
| CYTK | Cytokinetics | $10.6B | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCMNCT05767346results2026-06-09Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET) | Phase 3 | Completed | Drug: Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 175 | 2023-06-20 | 2025-02-28actual | — | 2026-06-09 |
| BMY | Bristol-Myers Squibb | $134.9B | COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)NCT06372457observationalParticipant age at Hypertrophic Cardiomyopathy (HCM) diagnosis | — | Active, not recruiting | Drug: Approved Hypertrophic Cardiomyopathy drug treatments, Mavacamten | Hypertrophic Cardiomyopathy (HCM) | 331 | 2023-12-01 | 2025-09-29actual | — | 2026-05-04 |
| BMY | Bristol-Myers Squibb | $134.9B | Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the USNCT07557498observationalParticipant blood pressure (both systolic and diastolic) | — | Recruiting | Drug: Mavacamten | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 362 | 2026-01-15 | 2026-12-14 | in 116 d | 2026-04-29 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)NCT07004972Incidence of serious Treatment Emergent Adverse Events (TEAEs) | Phase 4 | Active, not recruiting | Drug: Mavacamten | Symptomatic Obstructive Hypertrophic Cardiomyopathy | 50 | 2025-09-04 | 2027-12-13 | in 480 d | 2026-04-28 |
| TNYA | Tenaya Therapeutics | $157M | Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCMNCT05836259Number and severity of Adverse Events over the course of the study. | Phase 1/2 | Recruiting | Genetic: TN-201 | Hypertrophic Cardiomyopathy | 30 | 2023-08-10 | Aug 2027 | ≤ 376 d | 2026-03-19 |
| CYTK | Cytokinetics | $10.6B | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCMNCT05186818results2026-03-03Change From Baseline in pVO2 at Week 24 | Phase 3 | Completed | Drug: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 282 | 2022-02-01 | 2023-11-10actual | — | 2026-03-03 |
| CYTK | Cytokinetics | $10.6B | Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic CardiomyopathyNCT04219826results2026-02-24Incidence of Adverse Events (AEs) | Phase 2 | Completed | Drug: CK-3773274 (5 - 15 mg), CK-3773274 (10 - 30 mg), Placebo for CK-3773274 | Hypertrophic Cardiomyopathy (HCM) | 96 | 2020-01-10 | 2023-02-28actual | — | 2026-02-24 |
| BMY | Bristol-Myers Squibb | $134.9B | A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCMNCT03723655Frequency and severity of treatment-emergent adverse events and serious adverse events | Phase 2/3 | Completed | Drug: mavacamten | Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy, Non-obstructive Hypertrophic Cardiomyopathy | 314 | 2018-09-27 | 2026-01-16actual | — | 2026-02-20 |
| BMY | Bristol-Myers Squibb | $134.9B | Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in JapanNCT07383025observationalIncidence of adverse events (AEs) and/or serious AEs (SAEs) | — | Recruiting | Drug: Mavacamten | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 200 | 2025-05-21 | 2029-11-30 | in 1,198 d | 2026-02-03 |
| BMY | Bristol-Myers Squibb | $134.9B | Real-World Effectiveness of Mavacamten in CanadaNCT06338202observationalChange in New York Heart Association (NYHA) functional class following mavacamten treatment initiation | — | Completed | Drug: Mavacamten | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 115 | 2024-06-24 | 2024-11-12actual | — | 2025-12-04 |
| BMY | Bristol-Myers Squibb | $134.9B | Mavacamten Pregnancy Surveillance ProgramNCT05939700observationalPregnancy outcomes | — | Recruiting | Drug: Mavacamten | Breastfeeding, Hypertrophic Cardiomyopathy, Pregnancy Related | 20 | 2023-11-09 | 2027-04-30 | in 253 d | 2025-11-06 |
| BMY | Bristol-Myers Squibb | $134.9B | Mavacamten in Obstructive Hypertrophic CardiomyopathyNCT07168655observationalParticipant New York Heart Association (NYHA) functional class | — | Completed | Drug: Mavacamten | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 163 | 2023-02-21 | 2023-03-31actual | — | 2025-09-11 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the USNCT07107373observationalNew York Heart Association (NYHA) functional class | — | Active, not recruiting | Drug: Mavacamten | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 150 | 2023-12-22 | 2024-07-26actual | — | 2025-08-06 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in JapanNCT06181617observationalParticipant age | — | Completed | Other: Quality of life assessment | Hypertrophic Cardiomyopathy | 149 | 2023-12-06 | 2025-05-16actual | — | 2025-07-22 |
| CYTK | Cytokinetics | $10.6B | A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult SubjectsNCT03767855Incidence of Adverse events and Safety Signals observed during single and multiple ascending doses of CK-3773274 administered orally to healthy adult subjects. | Phase 1 | Completed | Drug: CK-3773274 - Granules in Capsule, Placebo - Granules in Capsule, CK-3773274 - Tablets | Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects | 114 | 2018-12-04 | 2020-01-03actual | — | 2025-01-24 |
| BMY | Bristol-Myers Squibb | $134.9B | Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEERNCT03496168results2025-01-09Number of Participants With Treatment Emergent Adverse Events and Treatment Emergent Serious Adverse Events | Phase 2 | Completed | Drug: mavacamten | Hypertrophic Cardiomyopathy | 13 | 2018-04-26 | 2023-11-09actual | — | 2025-01-09 |
| BMY | Bristol-Myers Squibb | $134.9B | Real-world Patient Reported Outcomes Among Patients Treated With CamzyosNCT06551129observationalParticipant Hypertrophic Cardiomyopathy symptoms as assessed by Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ v2,0 - 7-day recall version) | — | Recruiting | Drug: Mavacamten | Obstructive Hypertrophic Cardiomyopathy | 118 | 2024-05-10 | 2026-12-31 | in 133 d | 2024-11-07 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyNCT06146660observationalNumber of participants with adverse events | — | Recruiting | Drug: Mavacamten | Obstructive Hypertrophic Cardiomyopathy | 600 | 2024-07-24 | 2026-11-30 | in 102 d | 2024-11-06 |
| LIANY | LianBio LLC | $5M | A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCMNCT05174416results2024-09-19Change From Baseline to Week 30 in Valsalva Left Ventricular Outflow Tract (LVOT) Peak Gradient | Phase 3 | Completed | Drug: Mavacamten, Placebo | Obstructive Hypertrophic Cardiomyopathy | 81 | 2022-01-04 | 2023-03-06actual | — | 2024-09-19 |
| LIANY | LianBio LLC | $5M | Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese SubjectsNCT05135871results2024-07-25Area Under the Curve (AUC) (0-last), AUC(0-inf) | Phase 1 | Completed | Drug: Mavacamten | Hypertrophic Cardiomyopathy | 45 | 2021-10-31 | 2022-02-05actual | — | 2024-07-25 |
| GILD | Gilead Sciences | $177.9B | Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic CardiomyopathyNCT02291237results2018-03-22Change in Peak Oxygen Uptake (VO2) Achieved During Cardiopulmonary Exercise Testing (CPET) From Baseline to Week 24 | Phase 2/3 | Terminated | Drug: Eleclazine, Placebo | Hypertrophic Cardiomyopathy | 172 | 2015-02-05 | 2017-01-20actual | — | 2018-09-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Hypertrophic Cardiomyopathy is matched — 6 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Hypertrophic Cardiomyopathy
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Obstructive Hypertrophic Cardiomyopathy
- Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Hypertrophic Cardiomyopathy (HCM)
- Non-obstructive Hypertrophic Cardiomyopathy
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Hypertrophic Cardiomyopathy” (a text search, wider than this page)